38ac1da2-32a1-4530-a553-e5adff884b4f
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- ALLOGRAFT_REJECTION+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
- PANCREAS_BETA_CELLS+0.300
- BILE_ACID_METABOLISM+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
Top 10 suppressed
- G2M_CHECKPOINT-0.600
- E2F_TARGETS-0.500
- MITOTIC_SPINDLE-0.500
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.500
- WNT_BETA_CATENIN_SIGNALING-0.500
- HEDGEHOG_SIGNALING-0.300
- TGF_BETA_SIGNALING-0.300
- UV_RESPONSE_DN-0.300
- APICAL_JUNCTION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518255 | — | D | 0.879 |
| 2 | TCGA-86-A456-01A-11R-A24H-07 | — | cohortA1 | 0.876 |
| 3 | SRR25617861 | — | A | 0.873 |
| 4 | 39927c92-75d7-424c-9bcd-63def0075a1d | — | — | 0.860 |
| 5 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.858 |
| 6 | TCGA-85-A513-01A-12R-A26W-07 | — | cohortA1 | 0.858 |
| 7 | 94b2af92-0cfc-40b2-977d-6bd0fa4440d9 | — | — | 0.852 |
| 8 | SAMN03290938 | — | — | 0.852 |
| 9 | TCGA-MP-A4SW-01A-21R-A24X-07 | — | cohortA1 | 0.851 |
| 10 | ERR2598268 | fetal | fetal | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |